. 2019 Sep 13;38:403. doi: 10.1186/s13046-019-1409-3

Table 1.

Metabolism targeting approaches of T cell and tumor cells

Name	Target	Signaling pathway	Effect
PD-1/PD-L1 Anitibodies	PD-1/PD-L1	PI3K/Akt/mTOR	Teffs: increase FAO
PD-1/PD-L1 Anitibodies	PD-1/PD-L1	PI3K/Akt/mTOR	Tumor: inhibit glycolysis
CTLA-4 Antibodies	CTLA-4	PI3K/Akt/mTOR	Teffs: inhibit glucose uptake
Imatinib	BCR-ABL kinase/IDO	BCR/ABL IDO	Teffs: activate
			Treg: apoptosis
			Tumor: switching from glycolysis to OXPHOS
Metformin	PD-L1	LKB1-AMPK system mTOR	Tumor: down-regulate PD-L1 expression
PIM kinase inhibitor	PIM kinase	mTORC1	Teffs: increase glucose uptake
Enzyme phosphoenolpyruvate carboxykinase-1	Phosphoenolpyruvate	Sarco/ER Ca(2+)-ATPase (SERCA) activity	Teffs: upregulate the effector function
MVK inhibitor	MVK	PI3K/Akt/mTOR	Teffs: promote activation
MVK inhibitor	MVK	PI3K/Akt/mTOR	Tumor: inhibit
Avasimibe	ACAT-1	Cholesterol esterification	Teffs: activate
Avasimibe	ACAT-1	Cholesterol esterification	Tumor: inhibit the proliferation and metastasis
GDC-0919	IDO1	tryptophan	Teffs: relieves CD8+ T cell inhibition
INCB024360	IDO	tryptophan	Teffs: increase proliferation and IFN-γ production
N-acetylcysteine	FOXO1	PI3K/Akt/mTOR	Teffs: affect granzyme B secretion and PD-1 expression